Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

@article{Garcia2008PhaseIC,
  title={Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.},
  author={Agustin Garcia and H. Hirte and G. Fleming and D. Yang and D. Tsao-Wei and L. Roman and S. Groshen and S. Swenson and F. Markland and D. Gandara and S. Scudder and R. Morgan and Helen X. Chen and H. Lenz and A. Oza},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 1},
  pages={
          76-82
        }
}
  • Agustin Garcia, H. Hirte, +12 authors A. Oza
  • Published 2008
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, suppresses tumor growth, possibly by inhibiting angiogenesis. A phase II trial was conducted to evaluate the antitumor activity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent OC… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at… Expand
ConditionsOvarian Carcinoma, Primary Peritoneal Carcinoma
InterventionDrug
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
  • A. Gordon, N. Finkler, +4 authors E. Barrett
  • Medicine
  • International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2005
...
1
2
3
4
5
...